Jefferies Downgrades Tyra Biosciences to Hold, Raises Price Target to $31
Jefferies analyst Maury Raycroft downgrades Tyra Biosciences (NASDAQ:TYRA) from Buy to Hold and raises the price target from $19 to $31.
86 Biggest Movers From Yesterday
Gainers
FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million.
Tyra Biosciences Q3 EPS $(0.72) Up From $(1.47) YoY
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.72) per share. This is a 51.02 percent increase over losses of $(1.47) per share from the same period last year.
B of A Securities Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $22
B of A Securities analyst Geoff Meacham initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Buy rating and announces Price Target of $22.
Jefferies Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $19
Jefferies analyst Maury Raycroft initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Buy rating and announces Price Target of $19.
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 4)
44 Biggest Movers From Yesterday
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.